Intellia Therapeutics to Announce Q4 Earnings on February 26
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy NTLA?
Source: seekingalpha
- Earnings Announcement: Intellia Therapeutics is set to release its Q4 2023 earnings on February 26 before market open, with consensus EPS estimated at -$0.96 and revenue expected at $12.17 million, reflecting a 5.7% year-over-year decline, indicating potential challenges in R&D and market penetration.
- Market Sentiment: Analysts maintain a cautious outlook on Intellia, citing escalating risks particularly regarding the sustainability of its gene editing platform, which may undermine investor confidence in the company's future performance.
- FDA Guidance Impact: The FDA's guidance for rare disease pharmaceuticals could expedite development processes, and if Intellia effectively leverages this policy, it may enhance its market competitiveness and speed up product launches.
- Clinical Progress: Intellia's stock rose following the FDA's lifting of the clinical hold on its gene editing drug partnered with Regeneron, which could attract new investor interest and create market opportunities for the company.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NTLA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NTLA
Wall Street analysts forecast NTLA stock price to rise
22 Analyst Rating
9 Buy
12 Hold
1 Sell
Moderate Buy
Current: 13.580
Low
4.00
Averages
16.50
High
54.00
Current: 13.580
Low
4.00
Averages
16.50
High
54.00
About NTLA
Intellia Therapeutics, Inc. is a clinical-stage gene editing company focused on developing medicine with CRISPR-based therapies. CRISPR is a gene editing technology which is also sometimes referred to as CRISPR/Cas or CRISPR/Cas9 when referring to the use of CRISPR technology with the Cas9 enzyme. Its in vivo product candidates address genetic diseases by deploying its technologies, including CRISPR/Cas9 delivered by LNPs, as the therapy for diseases with high unmet need. Its lead in vivo product candidates, nexiguran ziclumeran (nex-z or NTLA-2001) for the treatment of transthyretin (ATTR) amyloidosis and NTLA-2002 for the treatment of hereditary angioedema (HAE), are the first CRISPR-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. For its ex vivo product candidates, it applies its technologies to create engineered cell therapies to address immuno-oncology and autoimmune diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Intellia Therapeutics to Announce Q4 Earnings on February 26
- Earnings Announcement: Intellia Therapeutics is set to release its Q4 2023 earnings on February 26 before market open, with consensus EPS estimated at -$0.96 and revenue expected at $12.17 million, reflecting a 5.7% year-over-year decline, indicating potential challenges in R&D and market penetration.
- Market Sentiment: Analysts maintain a cautious outlook on Intellia, citing escalating risks particularly regarding the sustainability of its gene editing platform, which may undermine investor confidence in the company's future performance.
- FDA Guidance Impact: The FDA's guidance for rare disease pharmaceuticals could expedite development processes, and if Intellia effectively leverages this policy, it may enhance its market competitiveness and speed up product launches.
- Clinical Progress: Intellia's stock rose following the FDA's lifting of the clinical hold on its gene editing drug partnered with Regeneron, which could attract new investor interest and create market opportunities for the company.
See More
FDA Unveils New Guidance to Accelerate Rare Disease Therapy Approvals
- Accelerated Approval Process: The FDA's draft guidance aims to expedite the approval of therapies for rare diseases, particularly focusing on individualized genome editing and RNA-based therapies, which is expected to significantly shorten time to market and enhance R&D enthusiasm among companies.
- Clear Treatment Focus: The new guidance emphasizes treatments targeting specific genetic, cellular, or molecular abnormalities, requiring sponsors to identify disease-causing abnormalities and demonstrate that therapies effectively target the underlying causes, thereby promoting the development of more targeted treatment options.
- Clinical Trial Flexibility: The FDA allows for the evaluation of different product variants targeting mutations in a single gene within a single product application, utilizing master protocols to assess these variants in one trial, which enhances the efficiency and flexibility of clinical trials.
- Beneficial Companies: Several companies, including Ultragenyx, Regenxbio, and CRISPR Therapeutics, could leverage the new framework, which is expected to drive innovation and competitiveness in the rare disease sector, further promoting growth in the biopharmaceutical industry.
See More
Intellia to Host Q4 and Full-Year 2025 Financial Results Call
- Conference Call Announcement: Intellia Therapeutics will host a conference call on February 26, 2026, at 8 a.m. ET to discuss its fourth quarter and full-year 2025 financial results, which is expected to provide important insights into the company's future strategies.
- Participation Details: U.S. callers should dial 1-833-316-0545, while international participants should call 1-412-317-5726, with a recommendation to join approximately five minutes before the call to ensure smooth access.
- Replay Availability: A replay of the call will be accessible on Intellia's website in the Investors & Media section for approximately 90 days, allowing investors who cannot attend live to obtain key information.
- Company Overview: Intellia Therapeutics focuses on leveraging CRISPR gene editing technology to develop innovative medicines aimed at addressing significant unmet medical needs and advancing treatment paradigms for patients, showcasing its leadership in the gene editing field.
See More
Intellia Therapeutics Regulatory Progress and Market Potential
- Regulatory Progress: Intellia Therapeutics' stock has risen 41% following the FDA's lifting of the clinical hold on nex-z, indicating market confidence in its potential treatment, although another study remains on hold, necessitating caution from investors.
- Market Opportunity: Intellia estimates that the HAE market will reach $6.3 billion by 2030, while the transthyretin amyloidosis market could hit $16.8 billion, highlighting significant market potential in rare diseases despite facing clinical and regulatory hurdles.
- Investment Risks: Even with the potential launch of nex-z and lonvo-z, the complexity and high costs associated with gene editing medicines may limit their market performance, prompting investors to weigh these risks, particularly in clinical-stage biotech investments.
- Industry Competition: Intellia's exclusion from The Motley Fool Stock Advisor's list of the top 10 stocks reflects a cautious market outlook on its future performance, suggesting that investors should consider more promising investment opportunities.
See More
Analysis of Intellia Therapeutics' Stock Recovery
- Stock Recovery Reasons: Intellia Therapeutics' stock surged 10.73% following the FDA's lifting of the clinical hold on nex-z, indicating a restoration of market confidence after regulatory setbacks, which is expected to enhance its future investment appeal.
- Significant Market Potential: Nex-z targets transthyretin amyloidosis, affecting 50,000 patients globally, while the HAE market is projected to reach $6.3 billion by 2030, showcasing Intellia's vast market opportunities in rare disease treatments.
- Ongoing Clinical Risks: Despite the lifting of the clinical hold on nex-z, Intellia still faces regulatory challenges with other studies, particularly with lonvo-z, which could impact stock price stability and investor confidence.
- Investment Risk Advisory: Given the complexity and high costs associated with gene editing medicines, Intellia's stock remains a high-risk investment, suggesting that investors with lower risk tolerance should approach with caution.
See More
FDA Lifts Clinical Hold on Intellia's IND for ATTRv-PN Trial
- Clinical Hold Lifted: The FDA lifted the clinical hold on Intellia Therapeutics' MAGNITUDE-2 Phase 3 trial, allowing the company to proceed with its investigational new drug application for hereditary transthyretin amyloidosis (ATTRv-PN), which is expected to positively impact future R&D progress.
- Increased Enrollment Target: Intellia has raised the target enrollment for the MAGNITUDE-2 trial from approximately 50 to 60 patients, aiming to enhance the reliability of study results and bolster market confidence in its treatment approach.
- Positive Efficacy Data: In the ongoing Phase 1 study, patients receiving a one-time dose of 0.3 mg/kg or higher (n=33) showed a 92% mean reduction in serum TTR levels at 24 months, indicating the long-term efficacy of nexiguran ziclumeran, which may boost investor confidence in Intellia.
- Enhanced Safety Monitoring: Intellia has agreed with the FDA to implement enhanced safety monitoring measures for liver laboratory tests in the MAGNITUDE-2 trial, addressing previous safety events and providing stronger safety assurances for future clinical trials.
See More
Intellia Therapeutics to Announce Q4 Earnings on February 26
- Earnings Announcement: Intellia Therapeutics is set to release its Q4 2023 earnings on February 26 before market open, with consensus EPS estimated at -$0.96 and revenue expected at $12.17 million, reflecting a 5.7% year-over-year decline, indicating potential challenges in R&D and market penetration.
- Market Sentiment: Analysts maintain a cautious outlook on Intellia, citing escalating risks particularly regarding the sustainability of its gene editing platform, which may undermine investor confidence in the company's future performance.
- FDA Guidance Impact: The FDA's guidance for rare disease pharmaceuticals could expedite development processes, and if Intellia effectively leverages this policy, it may enhance its market competitiveness and speed up product launches.
- Clinical Progress: Intellia's stock rose following the FDA's lifting of the clinical hold on its gene editing drug partnered with Regeneron, which could attract new investor interest and create market opportunities for the company.
See More
FDA Unveils New Guidance to Accelerate Rare Disease Therapy Approvals
- Accelerated Approval Process: The FDA's draft guidance aims to expedite the approval of therapies for rare diseases, particularly focusing on individualized genome editing and RNA-based therapies, which is expected to significantly shorten time to market and enhance R&D enthusiasm among companies.
- Clear Treatment Focus: The new guidance emphasizes treatments targeting specific genetic, cellular, or molecular abnormalities, requiring sponsors to identify disease-causing abnormalities and demonstrate that therapies effectively target the underlying causes, thereby promoting the development of more targeted treatment options.
- Clinical Trial Flexibility: The FDA allows for the evaluation of different product variants targeting mutations in a single gene within a single product application, utilizing master protocols to assess these variants in one trial, which enhances the efficiency and flexibility of clinical trials.
- Beneficial Companies: Several companies, including Ultragenyx, Regenxbio, and CRISPR Therapeutics, could leverage the new framework, which is expected to drive innovation and competitiveness in the rare disease sector, further promoting growth in the biopharmaceutical industry.
See More
Intellia to Host Q4 and Full-Year 2025 Financial Results Call
- Conference Call Announcement: Intellia Therapeutics will host a conference call on February 26, 2026, at 8 a.m. ET to discuss its fourth quarter and full-year 2025 financial results, which is expected to provide important insights into the company's future strategies.
- Participation Details: U.S. callers should dial 1-833-316-0545, while international participants should call 1-412-317-5726, with a recommendation to join approximately five minutes before the call to ensure smooth access.
- Replay Availability: A replay of the call will be accessible on Intellia's website in the Investors & Media section for approximately 90 days, allowing investors who cannot attend live to obtain key information.
- Company Overview: Intellia Therapeutics focuses on leveraging CRISPR gene editing technology to develop innovative medicines aimed at addressing significant unmet medical needs and advancing treatment paradigms for patients, showcasing its leadership in the gene editing field.
See More
Intellia Therapeutics Regulatory Progress and Market Potential
- Regulatory Progress: Intellia Therapeutics' stock has risen 41% following the FDA's lifting of the clinical hold on nex-z, indicating market confidence in its potential treatment, although another study remains on hold, necessitating caution from investors.
- Market Opportunity: Intellia estimates that the HAE market will reach $6.3 billion by 2030, while the transthyretin amyloidosis market could hit $16.8 billion, highlighting significant market potential in rare diseases despite facing clinical and regulatory hurdles.
- Investment Risks: Even with the potential launch of nex-z and lonvo-z, the complexity and high costs associated with gene editing medicines may limit their market performance, prompting investors to weigh these risks, particularly in clinical-stage biotech investments.
- Industry Competition: Intellia's exclusion from The Motley Fool Stock Advisor's list of the top 10 stocks reflects a cautious market outlook on its future performance, suggesting that investors should consider more promising investment opportunities.
See More
Analysis of Intellia Therapeutics' Stock Recovery
- Stock Recovery Reasons: Intellia Therapeutics' stock surged 10.73% following the FDA's lifting of the clinical hold on nex-z, indicating a restoration of market confidence after regulatory setbacks, which is expected to enhance its future investment appeal.
- Significant Market Potential: Nex-z targets transthyretin amyloidosis, affecting 50,000 patients globally, while the HAE market is projected to reach $6.3 billion by 2030, showcasing Intellia's vast market opportunities in rare disease treatments.
- Ongoing Clinical Risks: Despite the lifting of the clinical hold on nex-z, Intellia still faces regulatory challenges with other studies, particularly with lonvo-z, which could impact stock price stability and investor confidence.
- Investment Risk Advisory: Given the complexity and high costs associated with gene editing medicines, Intellia's stock remains a high-risk investment, suggesting that investors with lower risk tolerance should approach with caution.
See More
FDA Lifts Clinical Hold on Intellia's IND for ATTRv-PN Trial
- Clinical Hold Lifted: The FDA lifted the clinical hold on Intellia Therapeutics' MAGNITUDE-2 Phase 3 trial, allowing the company to proceed with its investigational new drug application for hereditary transthyretin amyloidosis (ATTRv-PN), which is expected to positively impact future R&D progress.
- Increased Enrollment Target: Intellia has raised the target enrollment for the MAGNITUDE-2 trial from approximately 50 to 60 patients, aiming to enhance the reliability of study results and bolster market confidence in its treatment approach.
- Positive Efficacy Data: In the ongoing Phase 1 study, patients receiving a one-time dose of 0.3 mg/kg or higher (n=33) showed a 92% mean reduction in serum TTR levels at 24 months, indicating the long-term efficacy of nexiguran ziclumeran, which may boost investor confidence in Intellia.
- Enhanced Safety Monitoring: Intellia has agreed with the FDA to implement enhanced safety monitoring measures for liver laboratory tests in the MAGNITUDE-2 trial, addressing previous safety events and providing stronger safety assurances for future clinical trials.
See More
